Department of Psychiatry and Behavioral Science, Tokyo Medical and Dental University Graduate School, Tokyo, Japan.
Department of Child and Adolescent Psychiatry, Kohnodai Hospital, National Center for Global Health and Medicine, Chiba, Japan.
PLoS One. 2021 Jun 3;16(6):e0252420. doi: 10.1371/journal.pone.0252420. eCollection 2021.
BACKGROUND/AIM: Patients with attention-deficit hyperactivity disorder (ADHD) manifest symptoms of hyperactivity, impulsivity, and/or inattention. ADHD medications available in Japan are limited compared with those in Western countries. Prescribing status has not been sufficiently evaluated in clinical settings in Japan. This study investigated the current use of ADHD medications and characteristics of patients who received multiple ADHD medications in a clinical setting in Japan.
Study participants were those who visited the Department of Child and Adolescent Psychiatry, Kohnodai Hospital between April 2015 and March 2020. We investigated patients who received osmotic-controlled release oral delivery system methylphenidate, atomoxetine, or guanfacine. A retrospective case-control design was used to evaluate the characteristics of patients who received multiple ADHD medications. Patients who were given three ADHD medications were defined as the case group. Randomly sampled sex- and age-matched patients diagnosed with ADHD were defined as the control group. We compared data for child-to-parent violence, antisocial behavior, suicide attempt or self-harm, abuse history, refusal to attend school, and two psychological rating scales (the ADHD-Rating Scale and Tokyo Autistic Behavior Scale).
Among the 878 patients who were prescribed any ADHD medications, 43 (4.9%) received three ADHD medications. Logistic regression revealed that children with severe ADHD symptoms, autistic characteristics, or tendency of child-to-parent violence were more likely to have been prescribed three medications during their treatment.
Our findings suggest the approach to prevent the use of multiple ADHD medications. A prospective study to investigate the causality between prescribing status and clinical characteristics is warranted.
背景/目的:患有注意力缺陷多动障碍(ADHD)的患者表现出多动、冲动和/或注意力不集中的症状。与西方国家相比,日本可获得的 ADHD 药物有限。在日本的临床环境中,尚未充分评估其开具情况。本研究调查了日本临床环境中 ADHD 药物的使用现状以及接受多种 ADHD 药物治疗的患者特征。
研究参与者为 2015 年 4 月至 2020 年 3 月期间访问神奈川医院儿童和青少年精神病学系的患者。我们调查了接受渗透控释口服传递系统哌甲酯、托莫西汀或胍法辛治疗的患者。采用回顾性病例对照设计评估接受多种 ADHD 药物治疗的患者特征。接受三种 ADHD 药物治疗的患者定义为病例组。随机抽取性别和年龄匹配的被诊断为 ADHD 的患者定义为对照组。我们比较了儿童对父母暴力、反社会行为、自杀企图或自残、虐待史、拒绝上学以及两种心理评定量表(ADHD 评定量表和东京自闭症行为量表)的数据。
在接受任何 ADHD 药物治疗的 878 名患者中,有 43 名(4.9%)接受了三种 ADHD 药物治疗。逻辑回归显示,具有严重 ADHD 症状、自闭症特征或儿童对父母暴力倾向的儿童在治疗期间更有可能被开三种药物。
我们的研究结果表明,需要采取措施预防使用多种 ADHD 药物。需要进行前瞻性研究,以调查开具情况和临床特征之间的因果关系。